Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

June 19, 2022

Study Completion Date

February 20, 2024

Conditions

COVID-19

Interventions

BIOLOGICAL

Inactivated COVID-19 Vaccine

600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection

Trial Locations (1)

Rushan City Center for Disease Control and Prevention, Weihai

All Listed Sponsors

lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY